Personalized solutions curated to maximize asset value at every opportunity.
With our connected suite of capabilities, we deliver best-in-class biotech services to clients. Our empowered experts bring deep expertise across therapeutic areas, helping to mitigate risks and maximize value at every stage.
We appreciate that sometimes you will need us more, and sometimes less, so we personalize our solutions to scale up or down, just as you need us. Always bringing you a value creation mindset to help maximize every opportunity.
Maximize the value of your asset at phase II clinical milestones.
We bring you personalized and dedicated services exactly when you need them because we understand that every day is a value creation opportunity. Our integrated biotech solutions are coordinated by a single strategic point of contact, who understands your business, bringing efficiencies and ensuring connectivity in the services provided.
Navigate this carousel with the arrows.
As EVP for Global Biotech Enterprise Solutions, Dean spearheads business development for Inizio efforts across our business units and agencies focused on emerging biotech organizations. Prior to this role commencing 1/1/22, Dean worked 5 years at STEM Healthcare, growing US business development and then as North America President. Before joining the healthcare services sector, Dean had an entire career at AstraZeneca, progressing through 16 roles with increasing responsibility in Sales, Training, Market Research, Marketing, Market Access, and US Executive Leadership.
Colin is Inizio’s Chief Commercial Officer and is responsible for our Commercial Activities and Business Development, with a particular emphasis on the support of our Large Enterprise Accounts and the infrastructure that supports our Global Sales Team. Prior to his current role, he was President of Inizio Advisory from September 2019, where he oversaw Inizio’s Consulting and Research Businesses. Before Inizio, Colin spent 20 years at ICON, where he held several leadership positions, including President of ICON Functional Services. Colin is a seasoned leader in the pharma industry, bringing 30 years of experience across both clinical development and commercialization. He has a strong track record of driving business growth, both organically and through M&A, and improving margins through process optimization.
Joining Ashfield in 2005 as a Regional Account Director in the UK, Greg Flynn has since worked with our teams across the UK, Japan and the US. He established and ran our joint venture in Japan before moving to the US in 2017 to lead Engage. Greg was previously the President of Engage from 2019 - 2025.
Reid Connolly leads Inizio Evoke, a global health marketing, communications, and transformation platform dedicated to making health more human™. Since founding Evoke in 2006, Reid has been instrumental in evolving the agency into one of the most progressive, client-centric, and people-first agencies in the industry, embracing its digital and data-driven roots to create a uniquely integrated platform. Reid has also been recognized by PRWeek as one of the industry’s top voices, with honors on both the Health Influencer 50 and Health Influencer 30 lists. Prior to founding Evoke, Reid held senior leadership roles at Digitas Health, imc2, and Saatchi & Saatchi Healthcare, where he honed his expertise in integrated healthcare marketing. He has partnered with leading pharmaceutical and biotech companies, including AstraZeneca, Amgen, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Novartis, and Pfizer.
Joining Medistrava in 2015, Elaine helped double the size of the organization through organic growth and acquisition to create a fully integrated medical, health economics and market access platform. Now, she joins us as President of Inizio Medical. As a trained neuropsychologist, Elaine has enjoyed a career in research and clinical practice before joining the industry, combining her background in science and behavior to drive evidence-based strategies that apply to real-world healthcare challenges.
We work in partnership with over 100 Biotech companies across the globe. We share our expertise from over 650 PhD’s, blending the science and commercial insight to guide, validate, and inspire the decisions that matter most.
Harness the collective expertise of our biotech experts to maximize the value of your asset across every step of your journey to commercialization.
J.P. Morgan recently held its 42nd annual healthcare conference in San Francisco, bringing together tens of thousands...
Emerging biotechs are increasingly recognizing the significance of data in driving innovation and ensuring the success...
Biopharma organizations and emerging biotechs must contend with a market in constant flux on their journey to product...
Leveraging our connected suite of capabilities, our experts will guide you through each pivotal moment in your asset’s lifecycle, creating tailored solutions that simplify the complex, unlock value, and enhance treatment outcomes.